CCP approves acquisition of global vaccine business (excluding influenza business except in China) by GSK from Novartis* The Competition Commission of Pakistan (CCP) has approved acquisition of the global vaccines business (excluding influenza business except in China) of Novartis AG by GlaxoSmithKline (GSK) after concluding the Phase II review of the pre-merger application and receiving commitments to address competition concerns. CCP initiated the Phase II review of the pre merger application received from GSK in November 2014 under section 11 of the Competition Act, 2010 to determine whether the
The Pakistan Competition Commission clears a merger subject to remedies in the pharmaceutical sector (GSK / Novartis)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.